Press Releases April 5, 2026 08:00 PM

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals Announces Participation in Key April 2026 Investor Conferences

By Ajmal Hussain PHAT
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
PHAT

Phathom Pharmaceuticals, a biopharmaceutical company specializing in gastrointestinal disease treatments, will have its management team participate in the Raymond James 2026 Biotech Innovation Symposium and the 25th Annual Needham Virtual Healthcare Conference in April 2026, including a fireside chat and one-on-one meetings. The company markets VOQUEZNA® products for GERD and H. pylori infections.

Key Points

  • Phathom will engage investors through key biotech and healthcare conferences in April 2026.
  • Management will conduct one-on-one meetings and participate in a fireside chat, enhancing investor communications.
  • The company markets VOQUEZNA® and related combination therapies for gastrointestinal conditions such as GERD and H. pylori infections.
  • Sectors impacted include biotechnology, pharmaceuticals, and healthcare markets.

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April:

Raymond James 2026 Biotech Innovation Symposium in New York, NY
Date: Tuesday, April 14, 2026
Management to participate in one-on-one meetings throughout the conference

25th Annual Needham Virtual Healthcare Conference
Date: Wednesday, April 15, 2026
Fireside Chat: 1:30 pm EDT
Management to participate in one-on-one meetings throughout the conference

To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
[email protected]

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
[email protected]

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.


Risks

  • Investor perception and conference outcomes may impact stock volatility and valuation.
  • Market competition in gastrointestinal therapeutics may affect commercial performance.
  • Regulatory and reimbursement environments remain uncertainties affecting future growth prospects.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026